SARS-CoV-2 Coronavirus Disease in Patients with Underlying Congenital Inferior Vena Cava Anomalies.

ingentiumby ingentium

In Clinical Literature.

Publication date: May 29, 2025

Background: COVID-19-related deep vein thrombosis (DVT) in patients with pre-existing congenital anomalies or genetic diseases of the cardiovascular system has been rarely reported, and a clear definition of best treatment in this setting remains undefined. Methods: We report the rare case of a 36-year-old male patient affected with a congenital cardiovascular anomaly, presenting extensive venous thrombosis following COVID-19-induced coagulopathy. An insight into current treatment strategies in this setting is also reported. Results and Conclusions: COVID-19 disease appears to be a determining factor in the development of extensive DVT in patients with congenital anomalies and genetic disorders. Anticoagulation should be tailored to the individual risk factors, balancing the risk-benefit between prevention of VTE and hemorrhagic complications.

Open Access PDF

Concepts Keywords
Biomedicines anticoagulation
Coronavirus COVID-19
Genetic COVID-19-associated coagulopathy
Rare deep vein thrombosis
Thrombosis

Semantics

Type Source Name
pathway KEGG Coronavirus disease
disease MESH Anomalies
disease MESH COVID-19
disease MESH deep vein thrombosis
disease MESH genetic diseases
disease MESH complications
drug DRUGBANK Coenzyme M
drug DRUGBANK Tretamine
disease IDO protein
disease IDO blood
disease MESH venous thromboembolism
disease MESH pulmonary embolism
disease MESH infection
disease MESH emergency
disease MESH edema
drug DRUGBANK Medical air
drug DRUGBANK Fibrinogen Human
disease IDO history
disease MESH respiratory alkalosis
disease MESH congenital abnormality
drug DRUGBANK Rivaroxaban
disease MESH thrombosis
disease MESH cytokine storm
pathway KEGG Platelet activation
disease MESH hypercoagulability
disease MESH viral infections
disease MESH influenza
disease MESH etiology
disease MESH obesity
drug DRUGBANK Enoxaparin
disease MESH renal insufficiency
drug DRUGBANK Heparin
drug DRUGBANK Creatinine
disease MESH critical illness
disease MESH bleeding
disease MESH long COVID
disease MESH clinical relevance
disease MESH malignancy
disease MESH chronic kidney disease
disease MESH acute kidney injury
disease MESH coronavirus infections
pathway REACTOME Influenza Infection
disease MESH leiomyosarcoma
drug DRUGBANK Fondaparinux
pathway REACTOME Hemostasis
disease MESH pneumonia
disease MESH Acute Pancreatitis

Original Article

(Visited 3 times, 1 visits today)